Study Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD4 CAR T cells in patients with relapsed and/or refractory T cell lymphoma.
Want to learn more about this trial?
Request More InfoInterventions
CD4 CAR T cellsBIOLOGICAL
CD4 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Peking University Shenzhen Hospital | Shenzhen | Guangdong | China |
| Chengdu Military General Hospital | Chengdu | Sichuan | China |